ArticleFrontiers in cardiovascular medicine2026
Research and development of novel embolization materials and study on their feasibility of preventing T2EL after EVAR abdominal aortic aneurysm.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to develop a novel vascular embolization material-Thrombin-Coated Controllable Coil (TCC)-and to evaluate its physicochemical properties, biological performance, and feasibility in preventing Type II Endoleak (T2EL) following Endovascular Aneurysm Repair (EVAR) for abdominal aortic aneurysm (AAA). Methods: TCC was prepared by coating an interlocking detachable coil (IDC) with a polyvinylpyrrolidone/polycaprolactone (PVP/PCL) blend containing lyophilized thrombin powder (LTP). Its morphology, dissolution, and thrombin-loading capacity were characterized. Coagulation efficiency was tested under static and dynamic conditions. The effects of TCC on vascular endothelial (VECs) and smooth muscle cells (VSMCs) were assessed Results: TCC exhibited a uniform thrombin coating layer, with an average drug loading of 0.0066 ± 0.0003 g, and the water solubility time was 1,080 ± 42.43 s. In the static and dynamic coagulation experiments, compared with the IDC group and the control group, TCC significantly shortened the coagulation time, and its coagulation efficiency was comparable to that of LTP. Extracellularly, TCC promoted apoptosis of VSMCs, inhibited the proliferation and migration of VSMCs, and had a relatively minor effect on VECs. Conclusion: TCC exhibits excellent biocompatibility, controllability, strong thrombogenic activity and safety. It is a highly promising next-generation embolic material for treating EVAR-related complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.